Investor Relations

Press Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
2/18/2020
8:00 AM ET
Press Release

Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106

2/18/2020

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
1/22/2020
8:30 AM ET
Press Release

Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

1/22/2020

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
12/9/2019
7:30 AM ET
Press Release

Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency

12/9/2019

MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID

Enhanced transd...

 Continue Reading
12/2/2019
8:30 AM ET
Press Release

Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

12/2/2019

NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
11/12/2019
7:30 AM ET
Earnings Release

Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

11/12/2019

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
Displaying 1 to 5 (of 81 releases)